Aardvark Therapeutics (AARD) said late Friday it paused its phase 3 trial of ARD-101 for hyperphagia in patients with Prader-Willi Syndrome after reversible cardiac observations at above target therapeutic doses were found during routine safety monitoring in a healthy volunteer study.

RBC downgraded the stock to sector perform from outperform. Other downgrades include HC Wainwright to neutral from buy.

Shares sank 56% Monday, with intraday trading volume of over 2.24 million against a daily average of about 191,000.

uniQure (QURE) shares tumbled 32% after the US Food and Drug Administration said data from the company's phase 1/2 trials was not sufficient to provide the primary evidence of effectiveness needed to support a marketing application for AMT-130, an investigational gene therapy for Huntington's disease.

More than 13.7 million shares traded intraday, compared with a daily average of about 2.64 million.

Price: 5.46, Change: -7.03, Percent Change: -56.29